Cancer is the highest-cost condition category in most employer-sponsored health plans, and survey data show it has stayed there for several years. In the 2024 Large Employer Health Care Strategy Survey from Business Group on Health, large employers named cancer as the leading condition driving their medical spend, ahead of musculoskeletal conditions, cardiovascular disease, diabetes, and mental health.
Total cancer spending sits lower than diabetes or heart disease because fewer employees have it in a given year. The difference is in per-case cost and claim concentration. The National Cancer Institute puts cancer-attributable medical costs at $208.9 billion in 2020, with a projection of $245 billion by 2030. The American Diabetes Association estimates direct medical costs of diagnosed diabetes at roughly $307 billion in 2022. Diabetes spreads high spending across millions of people. Cancer concentrates very high spending in a small number of employees each year.
Why cancer claims hit employer plans differently
Diabetes and cardiovascular disease are managed over years through primary care, medication, labs, and avoidable hospital admissions. Cancer billing is episodic and technology-heavy: surgery, radiation, infusion, imaging, pathology, emergency care for treatment side effects, and specialty drugs. Manufacturer list prices show why claims spike. CAR-T therapies list from roughly $373,000 to $475,000 per one-time treatment, and many oral oncology drugs list above $150,000 per year.
A cancer diagnosis also moves quickly. An employee may move from a routine screening to imaging, biopsy, surgery, and systemic therapy within weeks. That produces a tight cluster of high-dollar claims instead of the steady monthly spend typical of diabetes or hypertension. For a mid-sized employer, a handful of advanced cancer cases can change the year's medical loss ratio and stop-loss renewal price.
How the major conditions compare
- Cancer: lower prevalence than chronic disease but the highest per-case cost in employer plans. Specialty drugs, imaging, and hospital-based treatment dominate spend.
- Musculoskeletal conditions: high procedure volume across many employees, with predictable spending but large cumulative totals.
- Cardiovascular disease: large national cost base and high emergency and inpatient spend, spread more evenly across an older population.
- Diabetes: extremely high prevalence. Most cost is chronic medication, monitoring, and complication management.
- Mental health conditions: rising fast in employer plans, mostly in outpatient visits and prescriptions, with costs concentrated in younger, active employees.
Prevention and early detection change the math
The costliest cancer claims are often late-stage diagnoses. Detection stage is a documented driver of treatment cost, and earlier detection opens more treatment options. National preventive care data show only about 32% of adults get an annual physical and about 8% complete all recommended preventive care. That gap is where employers can act, because screening completion and clinical follow-up are measurable plan activities.
What employers can do
Four levers appear repeatedly in employer oncology cost management:
- Screen earlier. Track screening completion rates the way you track diabetes medication adherence.
- Manage site of care. Outpatient infusion can cost less than hospital outpatient departments for the same drug.
- Audit specialty drug claims. Cancer drugs dominate pharmacy spend and need tight medical-benefit review.
- Use centers of excellence. Bundled programs for complex cancer surgery can reduce complications and readmissions.
Where WellthCare™ fits
WellthCare™ builds preventive care into the front of the plan instead of leaving it to be scheduled after a diagnosis. Employees use $0-co-pay preventive services before claims hit the primary plan. Each plan of care is AI-drafted and reviewed by a nurse practitioner and physician, so a member who completes a health assessment or screening is connected to clinically reviewed follow-up. The Health-to-Wealth™ model then rewards verified preventive actions with dollars at the WellthCare Store™ and automatic retirement contributions funded by employer-committed savings.
No benefit eliminates cancer costs. The practical question is whether the plan improves screening completion, earlier detection, and care coordination before high-cost claims accumulate. That is the part of the oncology cost conversation employers can control.
Cancer will keep occupying the top line of employer cost surveys until something changes the timing of detection and the structure of treatment pricing. Employers who track screening rates, oncology spend by stage, and specialty drug claims will see the comparison in their own plan data. Ask your broker what your plan's oncology spend per 1,000 members looks like, and what share of cancer claims are identified at stage I or II.